Request Appointment
520 E 70th St# StarrNew York, NY 10021
Fax+1 212-746-7481
Overview of Dr. Ruan
Dr. Jia Ruan is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, New York-Presbyterian Hospital, and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from Weill Cornell Medicine and has been in practice 27 years. Dr. Ruan accepts several types of health insurance, listed below. She is one of 398 doctors at New York-Presbyterian Hospital and one of 123 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. She also speaks multiple languages, including Chinese (Mandarin). She has more than 100 publications and over 500 citings.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2003 - 2005
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2002 - 2003- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1999 - 2001
Weill Cornell MedicineClass of 1999
Certifications & Licensure
CA State Medical License 2000 - Present
NY State Medical License 2003 - 2026
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies Start of enrollment: 2007 Jun 01
- Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma Start of enrollment: 2011 Jul 29
- A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies Start of enrollment: 2012 Oct 01
Publications & Presentations
PubMed
- Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.Yucai Wang, Melissa C Larson, Steven R Hwang, Diego Villa, Laveniya Kugathasan
Blood Advances. 2026-02-24 - MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.Jia Ruan, David A Bond, Bijal Shah, John N Allan, Sarah C Rutherford
Blood Advances. 2026-02-24 - Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort Study.Jia Ruan, Zhengming Chen, Melissa C Larson, N Nora Bennani, Pamela Blair Allen
Blood Advances. 2026-02-18
Journal Articles
- Five-Year Follow-up of Lenalidomide plus Rituximab as Initial Treatment for Mantle Cell LymphomaJia Ruan, Jakub Svoboda, John P Leonard, Sonali M Smith, Morton Coleman, Richard R Furman, Blood
Abstracts/Posters
- A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell LymphomaJia Ruan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell_like (Non-GCB) Diffus...Jia Ruan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell LymphomasJia Ruan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Aggressive Non-Hodgkin Lymphomas: It's Getting Personal61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Rare Lymphomas: Desperately Seeking New TxsOctober 27th, 2023- Adding Azacitidine to Standard Chemotherapy May Be Effective for Patients with PTCL-TFHMay 15th, 2023
- Epigenetic Drug Aids Chemotherapy in Lymphoma StudyMay 9th, 2023
Professional Memberships
- Member
- Member
Other Languages
- Chinese (Mandarin)
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Choice
GHI PPO
Great West PPO
HIP of New York - Select PPOHumana ChoiceCare Network PPO
Lifewise Health Plan of Oregon
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
ODS Network
Oxford Health Freedom
Oxford Health Liberty
PacificSource Preferred PSN
Providence Health System Personal Option
Providence Health System Preferred PPO
Regence Oregon - Preferred Provider Network
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
